CSR activity report│Fighting Against COVID-19

Contribution to Global Supply of Therapeutic and Vaccine Candidates

Securing the production line for future COVID-19 therapeutics and vaccines

In May 2020, FUJIFILM Diosynth Biotechnologies (FDB)*1, a contract development and manufacturing organization (CDMO) of biologics, formed a partnership with the COVID-19 Therapeutics Accelerator (hereafter, the Accelerator), to support the development and supply of future COVID-19 therapeutics. The Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic. FDB was selected as a pharmaceutical partner by the Accelerator to reserve production capacity for the global supply of the drugs. We have already secured this capacity in our production facility in Denmark for the future mass production requirement.

Also, in July 2020, FDB agreed with Novavax, Inc., a U.S. biotechnology company, to manufacture the drug substance of NVX-CoV2373, a COVID-19 vaccine candidate developed by Novavax. Production is already in operation in our North Carolina site. We also plan to start production in the Texas site, as well as in the U.K. site in 2021. FDB continues to contribute to the prevention of further COVID-19 spread, and a termination of the pandemic through prompt supply of high-quality biologics suited to client needs across the world.

  • *1 FDB: Backed by its advanced production technologies and facilities, the company has a 30-year history as a CDMO covering a wide range of biologics, including antibodies, gene therapeutics, and vaccines. It can meet various needs in terms of small to large production lots, ranging from drug substance, drug product and packaging.
  • * This page contains some excerpts from the Sustainability Report 2020.